MedPath

GlaxoSmithKline Biologicals SA

🇧🇪Belgium
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

Clinical Trials

61

Active:57
Completed:2

Trial Phases

3 Phases

Phase 1:54
Phase 2:2
Phase 4:2

Drug Approvals

32

NMPA:19
EMA:12
FDA:1

Drug Approvals

Recombinant Zoster Vaccine(CHO Cell)

Product Name
欣安立适
Approval Number
国药准字SJ20190026
Approval Date
Mar 20, 2024
NMPA

Human Papillomavirus (Types 16,18) Vaccine, Adsorbed

Product Name
希瑞适
Approval Number
国药准字SJ20160025
Approval Date
Aug 10, 2021
NMPA

Human Papillomavirus (Types 16,18) Vaccine, Adsorbed

Product Name
希瑞适
Approval Number
国药准字SJ20160026
Approval Date
Aug 10, 2021
NMPA

Human Papillomavirus (Types 16,18) Vaccine, Adsorbed

Product Name
希瑞适
Approval Number
国药准字SJ20160027
Approval Date
Aug 10, 2021
NMPA

Recombinant Hepatitis B Vaccine (Saccharomyces cerevisiae)

Product Name
安在时
Approval Number
国药准字SJ20150022
Approval Date
Jul 12, 2020
NMPA

Recombinant Hepatitis B Vaccine (Saccharomyces cerevisiae)

Product Name
安在时
Approval Number
国药准字SJ20150020
Approval Date
Jul 12, 2020
NMPA

Recombinant Zoster Vaccine(CHO Cell)

Product Name
欣安立适
Approval Number
S20190026
Approval Date
May 21, 2019
NMPA

Recombinant Hepatitis B Vaccine(Saccharomyces cerevisiae)

Product Name
安在时
Approval Number
国药准字J20170019
Approval Date
Mar 15, 2017
NMPA

Recombinant Hepatitis B Vaccine(Saccharomyces cerevisiae)

Product Name
安在时
Approval Number
J20170019
Approval Date
Mar 15, 2017
NMPA

Recombinant Hepatitis B Vaccine(Saccharomyces cerevisiae)

Product Name
安在时
Approval Number
国药准字J20170020
Approval Date
Mar 15, 2017
NMPA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

Distribution across different clinical trial phases (59 trials with phase data)• Click on a phase to view related trials

Phase 1
54 (91.5%)
Phase 2
2 (3.4%)
Phase 4
2 (3.4%)
phase_1_2
1 (1.7%)
No trials found

News

No news found
© Copyright 2025. All Rights Reserved by MedPath